Although use of the term “theranostic” is relatively recent, the concept goes back to the
earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of …

The term theranostics is today perceived as the combination of a predictive biomarker with a
therapeutic agent. Use of this term began at the end of the last century and has steadily …

In the past four years most of the effort in radiopharmaceutical chemistry has been devoted
to compounds for positron emission tomography, but widespread use of this technique is still …

Molecular alterations in malignant disease result in the expression or upregulations of
various targets that can be used for imaging and treatment with radiopharmaceuticals. This …

Theranostics is a precision medicine which integrates diagnostic nuclear medicine and
radionuclide therapy for various cancers throughout body using suitable tracers and …

This review traces the development of targeted radionuclide therapy (TRT)(the Magic Bullet)
from the discovery of radioactivity in nature and the subsequent discovery of artificial …

Precision oncology is being driven by rapid advances in novel diagnostics and therapeutic
interventions, with treatments targeted to the needs of individual patients on the basis of …

There is an increasing role for positron emission tomography (PET) in oncology, particularly
as a component of early phase clinical trials. As a non‐invasive functional imaging modality …

Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of
neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled …

Introduction: Theranostics is an emerging field in which diagnosis and specific targeted
therapy are combined to achieve a personalized treatment approach to the patient. In …